Yes, Eliquis (apixaban) is an appropriate and often preferred alternative when a patient refuses Xarelto (rivaroxaban).
Both apixaban and rivaroxaban are FDA-approved direct oral anticoagulants (DOACs) that can be used interchangeably for most anticoagulation indications, and switching between them based on patient preference is clinically reasonable and commonly done. 1
Why Apixaban May Actually Be the Better Choice
The most recent evidence suggests apixaban may offer superior outcomes compared to rivaroxaban:
Lower bleeding risk: A 2026 meta-analysis of over 220,000 VTE patients found apixaban reduced major bleeding by 28% compared to rivaroxaban (RR 0.72; 95% CI 0.65-0.81) 2
Reduced recurrent thrombosis: The same study showed apixaban decreased recurrent VTE by 15% (RR 0.85; 95% CI 0.74-0.98) 2
Better net clinical benefit: When combining efficacy and safety, apixaban demonstrated 24% lower net clinical harm (RR 0.76; 95% CI 0.68-0.86) 2
Lower mortality in atrial fibrillation: A large Medicare study of 581,451 patients found rivaroxaban increased the composite of major ischemic/hemorrhagic events by 18% (HR 1.18; 95% CI 1.12-1.24) and total mortality by 6% (HR 1.06; 95% CI 1.02-1.09) compared to apixaban 3
Guideline Support
The 2026 ACC Scientific Statement specifically recommends apixaban as the preferred DOAC in certain high-risk populations including frail patients and those with prior bleeding history, citing its consistent benefit and lower bleeding risk 4. For patients with obesity (BMI ≥40), both rivaroxaban and apixaban are appropriate options 4.
Practical Prescribing Considerations
Dosing differs between the two agents 5:
- Apixaban: 10 mg twice daily × 7 days, then 5 mg twice daily (for VTE); 5 mg twice daily for atrial fibrillation
- Rivaroxaban: 15 mg twice daily × 21 days, then 20 mg once daily (for VTE); 20 mg once daily for atrial fibrillation
Dose reductions for apixaban (2.5 mg twice daily) apply when ≥2 of the following: age ≥80 years, serum creatinine ≥1.5 mg/dL, or weight ≤60 kg 5
Key pharmacokinetic advantage: Apixaban has more predictable absorption (food-independent, linear pharmacokinetics) compared to rivaroxaban (food-dependent, dissolution-limited absorption in proximal GI tract), making it more reliable in patients with GI issues 6
Critical Safety Points
When switching from rivaroxaban to apixaban 1:
- Do not leave a gap in anticoagulation - start apixaban when the next rivaroxaban dose would have been due
- Warn about premature discontinuation risk - stopping any DOAC without alternative coverage increases thrombotic risk
- Counsel on bleeding signs - both agents increase bleeding risk; patients need clear instructions on when to seek emergency care
- Check renal function - both require dose adjustment for CrCl 15-50 mL/min; apixaban is preferred if CrCl <30 mL/min as rivaroxaban should be avoided 5
Common Pitfalls to Avoid
- Don't overlap with parenteral anticoagulation unless treating acute VTE requiring lead-in dosing
- Don't use in mechanical heart valves - neither DOAC is approved for this indication 1
- Avoid in severe hepatic impairment (Child-Pugh C)
- Be cautious with neuraxial procedures - wait 24 hours after last apixaban dose before catheter removal; wait 5 hours after catheter removal before next dose 1
The patient's refusal of rivaroxaban actually presents an opportunity to prescribe what may be the superior agent based on current evidence.